Impaired Function of Treg Cells by Yamada, Akiko et al.
1 
Am J Pathol Regular Article 
Impaired Expansion of Regulatory T Cells in A Neonatal Thymectomy-Induced 
Autoimmune Mouse Model 
Akiko Yamada,* Aya Ushio,* Rieko Arakaki,* Takaaki Tsunematsu,* Yasusei Kudo,* 
Yoshio Hayashi,* and Naozumi Ishimaru* 
From Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University 
Graduate School, Tokushima, Japan 
Address correspondence to Naozumi Ishimaru, Department of Oral Molecular Pathology, Institute of 
Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramotocho, Tokushima 
770-8504, Japan E-mail: ishimaru.n@tokushima-u.ac.jp
This work was supported in part by the Funding Program for Next Generation World-Leading 
Researchers in Japan (LS090), a Grant-in-Aid for Scientific Research (no. 24659839 and no. 
24689068) from the Ministry of Education, Science, Sport, and Culture of Japan, and Uehara 
Memorial Foundation. 
Running title: Impaired function of Treg cells in a SS model 
Abbreviations used in this article: Tx, thymectomy; Treg cell, regulatroty T cell; SS, 
Sjögren’s syndrome; pTreg, peripherally induced Treg; tTreg, thymus-derived Treg 
© 2015. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
The published version is available via https://doi.org/10.1016/j.ajpath.2015.07.007.
  2 
Abstract 
Neonatal thymectomy (Tx) in certain mouse strains is known to induce organ-specific 
autoimmunity due to impaired functions of T cells, including Foxp3+ regulatory T (Treg) 
cells in the thymus. The precise mechanism underlying the induction of autoimmunity 
by neonatal Tx remains unclear. One possibility is that depletion of Treg cells breaks 
down peripheral tolerance. We examined the functions of Treg cells by using a murine 
Sjögren’s syndrome (SS) model, NFS/sld mice that underwent neonatal Tx. The ratio of 
Treg cells to effector memory phenotype T cells in Tx mice was significantly lower than 
that of non-Tx mice. In addition, in vitro induction of peripherally induced Treg cells by 
transforming growth factor-β (TGF-β) using naïve T cells from SS model mice was 
severely impaired. The mRNA expression of TGF-β receptor I, II, and Smad3 and -4 in 
the TGF-β-induced signal transduction pathway of Treg cells in this SS model were 
lower than those of control mice. In addition, Treg cells in this SS model exhibited an 
IFN-γ-producing Th1-like phenotype that resembled effector T cells. In conclusion, 
these results suggest that abnormal expansion and differentiation of Treg cells and 
inflammatory cytokines produced by Treg cells contribute to the development of 
autoimmunity. 
 
  
  3 
Introduction 
Neonatal thymectomy (Tx) in mice is a classical manipulation used to induce the 
breakdown of immunological tolerance. Tx in certain strains of mice triggers the onset 
of organ-specific autoimmune disease.1-9 However, the precise mechanism underlying 
Tx-induced organ-specific autoimmune disease remains unclear. Two possible 
mechanisms have been proposed to explain the association between lymphopenia and 
autoimmunity in Tx mice. One hypothesis is that Tx mice cannot sufficiently eliminate 
autoreactive T cells. A small population of autoreactive T cells is believed to readily 
interact with self-peptides presented on major histocompatibility complex (MHC) 
molecules of professional antigen-presenting cells (APCs) to become activated and 
expand. They then migrate to non-lymphoid organs, where autoimmune responses 
destroy and exert cytotoxic effects on target cells.10 Thus, the absence of sufficient 
numbers of Treg cells contributes to the onset of autoimmunity. In support of this 
hypothesis, CD4+CD25+ Treg cells were observed to differentiate in the thymus and 
circulate in the periphery after day 3, whereas CD4+CD25− T cells were produced 
before day 3 after birth. As a result, fewer Treg cells were present in adult Tx mice than 
in adult non-Tx mice.11 However, more recent studies have showed that Treg cells were 
present in the peripheral lymph nodes and spleen before or at day 3 after birth, although 
the absolute numbers of CD4+CD25+ T cells was lower in Tx mice than that in non-Tx 
mice.12,13 In addition, the immunosuppressive functions of Treg cells from Tx-mice were 
maintained.14 These results support the hypothesis that an insufficient number of Treg 
cells promotes the onset of autoimmunity. The role of Treg cells in autoimmunity 
induced by neonatal Tx remains unclear. 
     Another possibility derives from other recent studies presenting evidence that Treg 
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cells can also be generated outside of the thymus. These extrathymically generated Treg 
cells have been designated induced Treg (iTreg) or peripherally induced Treg (pTreg) cells. 
pTreg cells are converted from naïve CD4+ T cells in the presence of TGF-β and 
IL-2.15,16 In vitro, pTreg cells can acquire an immunosuppressive function similar to that 
of naturally occurring Treg (nTreg) or thymus-derived Treg (tTreg) cells.17,18 Several studies 
have shown that the adoptive transfer of pTreg cells generated ex vivo from naïve T cells 
can also prevent the development of autoimmune disease.15,19-22 Thus, if pTreg cells can 
sufficiently expand in the periphery, they may compensate for effective tTreg cells in 
neonatal Tx mice. The molecular mechanism underlying in vivo expansion of pTreg cells 
in Tx mice is completely obscure. 
     Sjögren’s syndrome (SS) is an autoimmune disease characterized by lymphocytic 
infiltrates and the destruction of salivary and lacrimal glands.23 We previously 
established an animal model for SS in NFS/sld mutant mice that were thymectomized at 
3 days after birth.9,24 These Tx NFS/sld mice developed autoimmune lesions in their 
salivary and lacrimal glands that resembled the lesions of human primary SS. The 
numbers of peripheral Treg cells in SS patients is significantly lower than that of healthy 
controls.25 We previously demonstrated that autoreactive CD4+ T cells played a pivotal 
role in the development of autoimmune exocrinopathy in these Tx NFS/sld mice.26 
However, whether Treg cells are involved in the molecular pathogenesis of SS remains 
unknown. 
   In the present study, we analyzed the effect of neonatal Tx on Treg subpopulations 
relative to numbers and effector functions in the NFS/sld mouse. In addition, the 
pathogenesis of autoimmunity in this neonatal Tx animal model was investigated with 
respect to expansion and function of Treg cells.   
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Material and Methods 
Ethics 
This study was conducted in accordance with the Fundamental Guidelines for Proper 
Conduct of Animal Experiments and Related Activities in Academic Research 
Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science 
and Technology of the Japanese Government. Our protocols were approved by the 
Committee on Animal Experiments of Tokushima University (Permit Number: 
toku-09021). 
 
Mice 
Female mice of the NFS/N strain that carried a mutant sld27 were reared in our specific 
pathogen-free mouse colony and provided food and water ad libitum. Thymectomy in 
NFS/sld and C57BL/6 (B6) mice from purchased from the Japan SLC Laboratory 
(Shizuoka, Japan) was performed on day 3 after birth. Neonatal and 8−18-week-old 
mice were used for experiments.  
  
Histology 
Salivary glands were removed from Tx and non-Tx mice, fixed with 10% 
phosphate-buffered formaldehyde (pH 7.2), and prepared for histological examination. 
Sections were stained with hematoxylin and eosin (H&E). 
 
Confocal microscopic analysis 
Frozen sections of the salivary glands from non-Tx and Tx mice were fixed with cold 
acetone, blocked with the M.O.M.™ blocking reagent (Vector Laboratories, Inc., 
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Burlingame, CA), and then stained with a biotinylated antibody against CD4 (Biolegend, 
San Diego, CA) and Alexa Fluor 568-conjugated streptavidin (Invitrogen, Carlsbad, 
CA) as a secondary antibody. After permeabilization with 0.2% Triton, sections were 
stained with a FITC-conjugated antibody against Foxp3. Nuclear DNA was stained with 
4′,6-diamino-2-phenylindole dihydrochloride (DAPI) (Invitrogen). Sections were 
observed with a laser scanning confocal microscope (Carl Zeiss, Jena, Germany) at 
400× magnification. Quick Operation Version 3.2 (Carl Zeiss) was used for image 
acquisition. 
 
Treg cell isolation  
Single-cell suspensions were prepared from spleen and cervical lymph nodes, after 
which CD4+CD25+ Treg cells were isolated using the EasySep purification kit (Stemcell 
Technologies, Vancouver, BC, Canada) according to the manufacturer’s instructions. 
Over 90% of the isolated Treg cells expressed intracellular Foxp3. 
 
Flow cytometric analysis 
The following monoclonal antibodies were purchased from eBioscience (San Diego, 
CA): anti-mouse CD4, CD8, GITR, CD25, Foxp3 and IL-17. Anti-Helios, IL-2, IL-4, 
IL-10, CD44, CD62L, and CD304 were purchased from Biolegend (San Diego, CA). 
Anti-CTLA-4, Bcl-xl, Bcl-2 and IFN-γ were purchased from BD Biosciences (San Jose, 
CA). Intracellular Foxp3 expression was analyzed using an intracellular Foxp3 
detection kit (eBioscience), according to the manufacturer’s instructions. For Bcl-xl and 
Bcl-2 staining, CD4+ T cells purified from spleen were stimulated with Dynabeads 
Mouse T-Activator CD3/CD28 (Life Technologies, Carlsbad, CA, USA) at a bead to 
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cell of 1:1 for 20 h. After washing, cells were stained with an anti-CD4 mAb, fixed in 
fixation/permeabilization solution, permeabilized in permeabilization buffer, and stained 
with anti-Bcl-xl or Bcl-2 and Foxp3 mAbs. For intracellular cytokine staining, 
lymphocytes from cervical lymph nodes were stimulated with 20 ng/ml of phorbol 
myristate acetate (PMA; Sigma-Aldrich, St. Louis, MO) and 500 ng/ml of ionomycin 
(Sigma-Aldrich) for 6 h in the presence of brefeldin A (eBioscience) for the last 4 h. 
Flow cytometric analysis was carried out using a BD FACSCant flow cytometer (BD 
Biosciences). Data were analyzed using FlowJo FACS Analysis software (Tree Star, 
Ashland, OR).  
 
Suppression assay 
Cell proliferation was determined using 5,6-carboxyfluorescein diacetate, succinimidyl 
ester (CFSE; Molecular probes, Eugene, OR, USA). Magnetically isolated CD4+CD25− 
conventional T cells (Tconv cells) were labeled with CFSE according to the 
manufacturer’s instructions. CFSE-stained CD4+CD25− Tconv cells (2.5 × 104/well) were 
incubated with purified Treg cells (2.5 × 104/well) for 3 days in the presence of 
Dynabeads Mouse T-Activator CD3/CD28 (Life Technologies) at bead to Treg cell ratios 
of 0.05, 0.1, and 0.25. 
 
Treg Expansion assay 
Treg cell expansion was assessed by CFSE dilution and cell counts. For the proliferation 
assay, CFSE-stained and magnetically isolated Treg cells (5 × 104 cells/well) were 
cultured with Dynabeads Mouse T-Activator CD3/CD28 at a bead to Treg cell ratio of 
0.25:1 and 100 U/ml of IL-2 (eBioscience) for 3 days. For cell counts, isolated Treg cells 
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(1 × 105 cells/well) were incubated for 7 days with Dynabeads Mouse T-Activator 
CD3/CD28 at a bead to Treg cell ratio of 2:1 and 2000 U/ml of IL-2.28 
 
Induction of Treg cells 
CD44lowCD62L+ naïve CD4+ T cells were purified from spleens using EasySep 
purification kits (Stemcell Technologies). Purified naïve CD4+ T cells (5 × 104 
cells/well) were cultured with Dynabeads® Mouse T-Activator CD3/CD28 (Life 
Technologies) at a bead:Treg cell ratio of 0.25:1 and 30 U/ml of IL-2 (eBioscience) in 
the presence of 1, 5, or 10 ng/ml of human TGF-β  PeproTech Inc., Rocky Hill, NJ). 
 
Adoptive Transfer of Treg cells into SS model 
Isolated naïve CD4+ cells from spleen in non-Tx and Tx NFS/sld mice were expanded 
for 3 weeks as described in Treg Expansion assay. 1× 106 Treg cells/mouse were 
transferred intravenously into Tx NFS/sld mice at 10 weeks of age. At 8 weeks after the 
transfer, the salivary gland tissues were removed, fixed with 10% phosphate-buffered 
formaldehyde (pH 7.2), and prepared for histological examination. Formalin-fixed 
tissue sections were subjected to hematoxylin-eosin (HE) staining, and three 
pathologists independently evaluated the histology without being informed of the 
condition of each mouse. The number of infiltrating lymphocytes in the salivary gland 
specimens was counted per 0.25 mm2.  
 
Quantitative RT-PCR analysis 
Total RNA was isolated from splenic naïve CD4+ T cells using RNeasy Plus Micro kits 
(Qiagen, Hilden, Germany). Total RNA was reverse transcribed using a PrimeScript RT 
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reagent kit (Takara Bio, Shiga, Japan). This cDNA was used as the PCR template. 
Transcript levels were determined using a 7300 Real-Time PCR System (Applied 
Biosystems, Foster City, CA) with SYBR Premix Ex Taq (Takara). The primer 
sequences used were as follows: TGF-β receptor I (TGF-βRI): forward, 
5′-AACTGAAACACCGTGGGAAC-3′ and reverse, 
5′-TGGGAAGCTTTCAGTTGACC-3′; TGF-βRII: forward, 
5′-CCCAGTCTGGAAATGAAAGC-3′ and reverse, 
5′-ACTTTTGTCGTGGGTTCTGG-3′; TGF-βRIII: forward, 
5′-TCAGATTTGTGCCTGTCTCG-3′ and reverse, 
5′-CTGGGTGTTCTGCATTTGTG-3′; Smad2: forward, 
5′-TCCCATTCCTGTTCTGGTCC-3′ and reverse, 
5′-ACTGCCCACACAAACCTTTC-3′; Smad3: forward, 
5′-TGATGGCTTCTGTTCTGGTG-3′ and reverse, 
5′-GGCACTTTCCTTTTGGACTG-3′; Smad4: forward, 
5′-ATGGCTATGTGGATCCTTCG-3′ and reverse, 
5′-TCAATCGCTTCTGTCCTGTG-3′; β-actin: forward, 
5′-GTGGGCCGCTCTAGGCACCA-3′ and reverse, 
5′-CGGTTGGCCTTAGGGTTCAGGGGG-3′. Relative mRNA expression of each 
transcript was normalized against β-actin mRNA. 
 
Enzyme-linked immunosorbent assay (ELISA) 
The concentration of IFN-γ in supernatants was measured by ELISA. 96-well 
flat-bottomed plates were pre-coated with capture antibodies, and diluted samples or 
standard recombinant cytokines were added to each well. After the plates were washed, 
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biotinylated antibodies were added, and the wells were incubated with horseradish 
peroxidase-labeled streptavidin. A solution of o-phenylenediamine (OPD; 
Sigma-Aldrich) was added to each well as the substrate. The optimal density at 490 nm 
was measured using a microplate reader (Model 680; Bio-Rad, Richmond, CA). 
 
Statistical analysis 
Results are presented as the means ± standard deviation (SD). Comparisons of the 
results between two groups were made by unpaired, two-tailed Student’s t-test. p <0.05 
was considered significant.  
 
Results 
Treg Cells in the Thymus and Spleen of Neonatal Mice at 3 and 7 Days after Birth  
We first analyzed Foxp3-expressing Treg cells in the thymus and spleen of neonatal 
NFS/sld mice without Tx. There were no differences in the proportions of Foxp3+ Treg 
cells in the thymus between 3 and 7 day after birth (Figure 1A). The proportions of 
Foxp3+ Treg cells in the spleen of both 3-day- and 7-day-old mice were approximately 
12−13% (Figure 1B), although the numbers of Foxp3+ Treg cells in the spleen of 
7-day-old mice were dramatically increased, along with an increase in CD4+ T cells 
(Figure 1C). These results suggest that the expansion of peripheral Treg cells during the 
neonatal period may be involved in the maintenance of the peripheral tolerance by Treg 
cells.  
 
Number of Peripheral Treg Cell in the Tx SS Model 
Next, we investigated Treg cells in Tx NFS/sld mice (Tx mice) used as an SS model at 
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10 weeks of age. Although the proportion of Foxp3+ Treg cells among CD4+ T cells in Tx 
mice was higher than that in non-Tx control mice (Figure 2A), the actual number of Treg 
cells in both the spleen and cervical lymph nodes (CLNs) of Tx mice was significantly 
lower than that in non-Tx mice (Figure 2C). In addition, the number of CD4+ T cells in 
Tx mice was significantly lower than that in non-Tx mice (Figure 2C).  
     The proportion of CD44highCD62L− effector memory phenotype CD4+ T cells of 
the spleen and CLNs was dramatically higher in Tx mice than in non-Tx mice (Figure 
2D). In addition, the ratio of Treg cells to effector memory T cells in the spleen and 
CLNs of Tx mice was significantly lower than that of non-Tx mice (Figure 2E). 
     To assess whether Treg cells had migrated into the salivary glands as a target organ 
in Tx mice, Foxp3+Treg cells were examined using a confocal microscope. 
Foxp3+CD4+Treg cells had infiltrated into the salivary glands of Tx mice (Figure 2F). 
These results indicate that the number of Treg cells may be insufficient to suppress 
effector T cells for the induction of autoimmune lesions in target organs of Tx mice.  
 
Suppressor Function of Treg Cells in Tx Mice 
Next, the regulatory function of Treg cells in Tx mice was investigated. To assess the 
phenotypes of Treg cells, we examined the expression of hallmark proteins in Treg cells, 
including cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and 
glucocorticoid-induced tumor necrosis factor-receptor (GITR). The CTLA-4 expression 
levels on Foxp3+ CD4+ Treg cells from the spleen and CLNs of Tx mice were similar to 
those of cells derived from non-Tx mice (Figure 3A). In addition, there was no 
difference in GITR expression on Treg cells from the spleen and CLNs from Tx and 
non-Tx mice (Figure 3A).  
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     Next, we used an in vitro suppression assay to evaluate the function of Treg cells. 
CD4+ CD25− effector T cells from non-Tx mice were labeled with CFSE and cultured 
for 72 h together with unlabeled CD4+CD25+ Treg cells in the presence of 
anti-CD3/CD28 mAbs. Treg cells from both non-Tx and Tx mice suppressed the 
proliferation of effector T cells (Figure 3B). In addition, there was no difference in Treg 
cell suppression activity between cells derived from Tx and non-Tx mice when using 
CD25−CD4+ T cells from Tx mice as effector cells (Supplementary Figure 1). 
Furthermore, there was no significant difference in the suppression function of Treg cells 
from non-Tx and Tx mice by in vitro suppression assay with different ratios of effector 
and Treg cells (Supplementary Figure 2). These results suggest that Treg cells from Tx 
mice have the same in vitro immunosuppressive ability as those from non-Tx mice. 
     To determine the in vivo suppression activity of Treg cells in Tx mice, adoptive 
transfer of Treg cells from non-Tx and Tx mice was performed using Tx mice as 
recipients and the presence of autoimmune salivary gland lesions was evaluated. The 
number of lymphocytes infiltrating into the target tissue in Tx mice was significantly 
reduced by the transfer of Treg cells from non-Tx mice while the inflammatory lesion 
was not completely protected (Figure 3C, D). Although the number of infiltrating 
lymphocytes in Tx Treg cell-transferred mice was significantly lower than that of 
non-transferred Tx mice, the number of infiltrating lymphocytes in the Tx Treg 
cell-transferred mice was significantly higher than that of non-Tx Treg cell-transferred 
mice (Figure 3C, D). This result suggests that the suppression function of Treg cells of 
Tx mice may be not sufficient for controlling autoimmunity in vivo.  
 
Treg Cell Expansion in Tx Mice 
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To investigate the peripheral expansion of Treg cells in Tx mice, CFSE-labeled Treg cells 
were stimulated with anti-CD3/28 mAbs in the presence of IL-2 for 3 days. Interestingly, 
the proliferation of Treg cells from Tx mice was significantly lower than that of Treg cells 
from non-Tx mice (Figure 4A). After 7 days of Treg cell culture, the total number of Treg 
cells from Tx mice was markedly lower than that from non-Tx mice (Figure 4B). 
Because the IL-2−IL-2R signaling pathway plays a pivotal role in the generation, 
homeostasis, and expansion of Treg cells,29,30 we examined IL-2R receptor (CD25 
protein) expression on the surface of Treg cells. Surface CD25 expression on Treg cells 
did not differ between cells from Tx and non-Tx mice (Figure 4C).  
    We next examined the expression of Bcl-xl and Bcl-2, anti-apoptotic members of 
the Bcl-2 family. Stimulation with anti-CD3/28 mAbs up-regulated Bcl-xl and Bcl-2 
protein levels in Foxp3−CD4+ T cells, although there was no increase in Bcl-xL and 
Bcl-2 expression in Treg cells of either Tx or non-Tx mice (Figure 4D, E). These results 
suggest that the impaired expansion of Treg cells in Tx mice may involve a pathway 
independent of survival signaling by the Bcl-2 family. 
 
pTreg Cell Expansion in Tx NFS/sld Mice 
While tTreg cells are derived from thymic differentiation, it is now apparent that 
conventional peripheral naïve CD4+ T cells can be converted to Foxp3+ Treg cells, called 
pTreg cells.17 The transcription factor Helios is one of the markers that can be used to 
discriminate between tTreg cells and pTreg cells.31 Thus, we analyzed these Treg cell 
subsets in Tx mice using Foxp3 and Helios expression.  
     The numbers of both Helios+ Foxp3+ tTreg cells and Helios− Foxp3+ pTreg cells in 
the spleen and CLNs of Tx mice were significantly lower than those of non-Tx mice 
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(Figure 5A). In contrast, the proportion of tTreg cells in the spleen and CLNs of Tx mice 
was considerably higher than that of non-Tx mice (Figure 5B). The ratio of pTreg cell to 
tTreg cells in the spleen and CLNs of Tx mice was significantly lower than that of 
non-Tx mice (Figure 5B). Another marker, CD304 (Neuropilin-1) expressed in the Treg 
cell subset,32 was used to distinguish pTreg and tTreg cells in Tx mice. The ratio of 
CD304−/low Foxp3+ pTreg cells to CD304high Foxp3+ tTreg cells of both spleen and CLNs 
was significantly lower in Tx mice than that in non-Tx mice (Figure 5C). These findings 
suggest that the differentiation of pTreg cells is impaired in Tx mice.  
  
In Vitro Induction of pTreg Cells 
Although a reduction in tTreg cell numbers was expected in Tx mice, it was unclear why 
the expansion or maintenance of pTreg cells was impaired. To elucidate the mechanism 
underlying pTreg cell maintenance, purified CD44lowCD62L+ naïve CD4+ T cells from 
the spleen of non-Tx and Tx mice were cultured with anti-CD3/CD28 mAbs in the 
presence of IL-2 and TGF-β to differentiate and expand them into pTreg cells. The 
differentiation of naïve CD4+ T cells to Helios−Foxp3+ pTreg cells from Tx mice was 
significantly suppressed compared with that of naïve CD4+ T cells from non-Tx mice 
(Figure 6A, B). 
     Whether expansion of pTreg cells in Tx-treated C57BL/6 (B6) mice is impaired 
was unclear. Purified naive T cells of spleen from non-Tx and Tx B6 mice were cultured 
with anti-CD3/CD28 mAbs in the presence of IL-2 and TGF-β for 7 days. 
Helios−Foxp3+ pTreg cells from Tx B6 mice were also significantly suppressed 
compared with that of naïve CD4+ T cells from non-Tx B6 mice (Supplemental Figure 
3). The result suggests that Tx induces impaired differentiation and expansion of pTreg 
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cells in any mouse strain.    
 
TGF-β Receptor and Smad Expression on Naïve T Cells from Tx Mice 
Because TGF-β signaling is important for the generation of pTreg cells,15 we examined 
the mRNA expression of TGF-βRI, TGF-βRII, and TGF-βRIII in CD4+CD25− T cells. 
TGF-βRI and TGF-βRII mRNA expression levels in these cells from Tx mice were 
significantly lower than those in cells from non-Tx mice (Figure 7). In addition, the 
mRNA expression of Smad3 and -4, key molecules for TGF-β receptor signaling during 
pTreg expansion,33-35 in cells from Tx mice were also significantly lower in cells from Tx 
mice than in those from non-Tx mice (Figure 7). These results suggest that the 
differentiation and expansion of pTreg cells via the TGF-β/Smad pathway in the 
periphery of Tx mice was impaired in addition to the decreased generation of tTreg cells 
in the thymus.  
 
Treg Cells from Tx Mice Produce IFN-γ 
Treg cells employ several mechanisms, including cell-to-cell contact, for achieving 
immune suppression.36,37 In contrast, the anti-inflammatory cytokine IL-10 is required 
for in vivo suppression.38-40 In addition, several studies have indicated that Treg cells 
produce pro-inflammatory effector cytokines such as IFN-γ and IL-17 under certain 
specific conditions and in some autoimmune diseases.41-44 To explore the cytokine 
production profile of the peripheral total CD4+ T cells including Treg cells and effector T 
cells in Tx mice, we examined intracellular cytokine production in purified CD4+ cells 
after stimulation with PMA/ionomycin.  
     Foxp3−CD4+ effector cells from Tx mice produced elevated levels of IFN-γ and 
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IL-4 (Figure 8A). There was no evidence for increased expression of IL-2, IL-17, or 
IL-10 by these cells from Tx mice (Figure 8A). However, Treg cells, including tTreg and 
pTreg cells, from Tx mice also produced large amounts of IFN-γ and IL-4, resembling 
the profile of effector cells (Figure 8B). There were no differences in IL-2, IL-17, or 
IL10 production between cells from non-Tx and Tx mice (Figure 8B). IFN-γ production 
by Treg cell subsets was analyzed using flow cytometry, indicating that IFN-γ production 
by CD62L−IFN-γ+ cells in both pTreg and tTreg cells stimulated with PMA/ionomycin 
was significantly higher in those from Tx mice than from non-Tx mice (Figure 8C, D).  
    To measure IFN-γ secretion from expanded Treg cells of Tx mice, purified Treg cells 
were stimulated with anti-CD3/28 mAbs in the presence of IL-2 for 10 days. The 
supernatants from 0−3 and 7−10 days were analyzed by ELISA. The IFN-γ 
concentration in the supernatant from Treg cells of Tx mice was significantly higher than 
that of non-Tx mice (Figure 8E). These results suggest that Treg cells in Tx mice may 
have an effector-like phenotype that is associated with the development of 
autoimmunity. 
 
Discussion  
Peripheral T cell expansion, including that by Treg cells, is vigorously promoted during 
the neonatal period. In this study, we focused on the dynamics and functions of Treg cells 
derived from neonatal Tx mice to determine the relationship between Treg cells and 
autoimmunity in these mice. Our results showed that a reduction in Treg cell numbers in 
the periphery of Tx mice influenced the onset of autoimmune disease in our model, 
which was in accordance with the results of previous reports of other thymectomized 
models.1-9 Thus, the expansion ability of Treg cells in Tx mice was insufficient to 
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compensate for the shortage in Treg cell numbers.  
   We showed that induction of Treg cells from peripheral naive CD4+ T cells was 
suppressed in Tx mice. Although the in vivo function of pTreg cells remains uncertain, 
several studies have reported that pTreg cells suppress inflammation in autoimmune 
and/or inflammatory diseases such as asthma, SLE, type 1 diabetes, gastritis, colitis, and 
MS.15,19-22,45 The results of the present study demonstrate that a reduced ratio of Treg 
cells to effector T cells may influence the onset or development of autoimmunity in Tx 
mice and suggest that neonatal thymectomy interferes with the differentiation and 
expansion of pTreg cells from naïve T cells. Several markers of Treg cell subsets have 
been reported, including Helios and CD304.31,32,46 In the present study, a reduction of 
the ratio of pTreg cells to tTreg cells using Helios and CD304 was observed in Tx mice. 
Helios is known to be one of the ikaros family of transcription factors important for the 
differentiation of tTreg cells.31 CD304 is also a surface marker of tTreg cells.32 
   TGF-β plays a key role in the generation and expansion of Treg cells. TGF-β 
signaling is required for the development of tTreg cells in the thymus, possibly by 
promoting their survival.15 In addition, TGF-β promotes the differentiation and 
expansion of pTreg cells by promoting Foxp3 expression in naïve T cells.15 The binding 
of TGF-β to TGF-βR activates the structurally similar transcription factors Smad2 and 
Smad3 in target cells.47 Activated Smad2 or Smad3 heterodimerizes with Smad4 
followed by translocation into the nucleus to regulate target gene expression.48 However, 
there are also Smad-independent pathways that mediate TGF-βR signaling.48  
     TGF-β induces the rapid activation of TGF-β–activated kinase 1, Ras-Erk, and 
PI3K-Akt pathways.48 In the present study, mRNA expression of TGF-βRII, TGF-βRIII, 
Smad2, and Smad3 in naïve T cells was reduced after neonatal thymectomy, suggesting 
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that there may be many mechanisms for maintaining the expression of key genes for T 
cell survival and function in the neonatal thymus. The present study suggests an 
important possibility that effector T cells may be resistant to the Treg cell-mediated 
suppression, which is consistent with the finding that lower levels of TGF-βR and Smad 
are expressed in naïve T cells in this model. 
    We also found that Treg cells from Tx mice had different cytokine production 
profiles compared with those from control mice. The cells from Tx mice preferentially 
produced a pro-inflammatory cytokine, IFN-γ, similar to activated conventional CD4+ T 
cells. Recent studies have suggested that Treg cells are capable of secreting 
pro-inflammatory cytokines for maintaining Foxp3 expression.41,44,49-51 In contrast, an 
IFN-γ-induced molecule, interferon regulatory factor 1, reportedly bound to the Foxp3 
promoter region and inhibited Foxp3 expression.52 Furthermore, recent reports have 
demonstrated that Foxp3 expression in Treg cells is unstable and that Treg cells not 
expressing Foxp3 can be converted to effector cells when they encounter an 
inflammatory milieu.53-56 In the present study, the number of infiltrating lymphocytes 
differed between transfer of Tx Treg cells and transfer of non-Tx Treg cells even though 
there was no difference in in vitro suppression between non-Tx and Tx Treg cells. Thus, 
it is possible that Treg cells in Tx mice exhibit an effector cell-like phenotype that does 
not fully promote autoimmunity in addition to the reduced Treg cell numbers observed in 
Tx mice.  
   Neonatal immune responses are considered to be immunologically immature.57 In 
addition, the neonatal T cell repertoire is more pathogenic than that of adults.56 Thus, T 
cell differentiation and development in the neonatal thymus potently contributes to 
maintaining immune tolerance in the periphery. Neonatal thymectomy is one of the 
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traditional manipulations used to induce organ-specific autoimmune diseases in various 
organs, including stomach, testis, prostate, ovary, thyroid gland, salivary gland, and 
lacrimal gland.1-9 We established a murine model for SS using the NFS/sld mouse strain 
that underwent neonatal Tx.9,25 We investigated the pathogenesis of and new therapeutic 
strategies for SS using this model.58-60 Impaired Treg cells are known to contribute to the 
onset or development of SS.61 However, whether the expansion or function of pTreg cells 
influences the pathogenesis of SS remains unclear. In the present study, we focused on 
the unique phenotype and function of Treg cells in this SS model to elucidate the 
relationship between Treg cells and organ-specific autoimmunity.  
   In conclusion, Treg cells in Tx mice were insufficient for regulating effector T cells 
and protecting autoimmunity with respect to cell numbers and function. The results of 
this study will be useful for understanding the pathogenesis of Tx-induced autoimmune 
diseases and the development of new autoimmunity therapies with Treg cells.  
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Figure legends 
Figure 1 Numbers of Treg cells in the thymus and spleen of neonatal mice at 3 and 7 
days after birth. A, B: CD4/CD8 and CD4+Foxp3+ cell populations in the thymus (A), 
and spleen (B) from non-Tx NFS/sld mice at 3 and 7 days after birth was assessed by 
flow cytometry. C: Numbers of CD4+ T cells and Foxp3+CD4+ T cells in the spleen of 
non-Tx mice were determined. Results are presented as the mean ± SD for 5 mice per 
condition.  
 
Figure 2 Numbers of Treg cells in peripheral lymphoid tissues. A: Frequency of Foxp3+ 
cells gated on CD4+ cells in spleen and cervical lymph nodes (CLNs) of non-Tx and Tx 
mice at 10 weeks of age was determined by flow cytometry. Results are representative 
of 5 mice per each group. Results are presented as the mean ± SD of 5 mice per group. 
*p <0.05 vs. non-Tx mice. B: Numbers of CD4+ and Foxp3+CD4+ T cells in the spleen 
and CLNs of non-Tx and Tx mice were determined by flow cytometry. Results are 
presented as the mean ± SD of 5 mice per group. *p <0.05, **p <0.01 vs. non-Tx mice. 
C: Effector memory phenotype of CD4+ T cells in spleen and CLNs was analyzed by 
flow cytometry. Results are representative of 5 mice. Ratio of effector/memory to naïve 
T cells is presented as the mean ± SD of 5 mice per group. *p <0.05, **p <0.01 vs. 
non-Tx mice. D: Ratio of Treg to effector/memory T cells is presented as the means ± SD 
of 5 mice per group. *p <0.05 vs. non-Tx mice. E: Histological analysis of salivary 
glands (SGs) from Tx mice (H&E staining; left). Scale bar: 100µm. CD4+ T cells (red), 
Foxp3+ cells (green), and cell nuclei (blue) in SGs were observed under a confocal 
microscope (right). Results are representative of 5 mice. Scale bar: 10 µm. 
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Figure 3 Surface phenotypes and immunosuppressive functions of Treg cells. A: 
CTLA-4 and GITR expressions on CD4+Foxp3+ cells in the spleen and CLNs of non-Tx 
and Tx mice at 10−12 weeks of age were determined by flow cytometry. Solid lines 
indicate CD4+Foxp3+ cells from Tx mice and dotted lines indicate these cells from 
non-Tx mice. The isotype control is shaded on each graph. Representative results of 3 
independent experiments are shown. B: CFSE-labeled CD4+CD25− T cells (2.5 × 104 
cells/well) from Tx mice were cultured with unlabeled Treg cells (2.5 × 104/well) from 
non-Tx and Tx mice along with anti-CD3/28 mAb-coated beads at bead to cell ratios of 
0.05:1, 0.1:1, and 0.25:1. After culture for 3 days, CD4+CD25− T cell division was 
determined by CFSE dilution. Representative results of 3 independent experiments are 
shown. C: Treg cells (1 × 106 cells) expanded from naïve CD4+ T cells of spleen in 
non-Tx and Tx mice were transferred intravenously into Tx mice. 8 weeks later salivary 
gland tissues of the recipient mice were histopathologically analyzed. Photos are 
representative of 5 mice per group. Scale bar: 100 µm. D: The number of infiltrating 
lymphocytes in 0.25 mm2 of salivary gland tissue was counted, and results are presented 
as the mean ± SD of 5 mice per group. *p <0.05, ***p <0.005 vs. Tx mice.   
 
Figure 4 Treg cell expansion in Tx mice. A: CFSE-labeled purified Treg cells (5 × 104 
cells/well) from non-Tx and Tx mice were cultured with anti-CD3/28 mAbs-coated 
beads at a bead: to cell ratio of 0.25:1 and 100 U/ml of IL-2. After culture for 3 days, 
Treg cell division was determined by CFSE dilution. Results are presented as the mean ± 
SD of 3 mice per group. *p <0.05 vs. non-Tx mice. B: Treg cells (1 × 105 cells/well) 
from the spleen of non-Tx and Tx mice were stimulated with anti-CD3/28 mAbs-coated 
beads at a 2:1 bead to cell ratio and 2000 U/ml of IL-2 for 7 days. Open circles indicate 
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CD4+Foxp3+ cells from non-Tx mice and closed circles indicate those from Tx mice. 
Results are presented as the mean ± SD of 3 independent experiments. **p <0.01 vs. 
non-Tx mice. C: CD25 expression on CD4+Foxp3+ cells from the spleen and CLNs of 
non-Tx (dotted lines) and Tx (solid lines) mice was determined by flow cytometry. 
Results are representative of 5 mice per group. D, E: CD4+ T cells (2 × 105 cells/well) 
from the spleen of non-Tx and Tx mice were cultured with anti-CD3/28 mAbs-coated 
beads at a 1:1 bead to cell ratio. After culture for 20 h, Bcl-xl and Bcl-2 expression in 
Foxp3−CD4+ and Foxp3+CD4+ cells was determined by flow cytometry. Results are 
representative of 3 independent experiments.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 
Figure 5 pTreg cells in Tx mice. A: Numbers of Foxp3+CD4+ cells, Foxp3+Helios+CD4+ 
cells, and Foxp3+Helios−CD4+ cells in the spleen and CLNs of non-Tx and Tx mice at 
10 weeks of age were determined by flow cytometry. Results are presented as the mean 
± SD of 3 mice per group. *p <0.05 vs. non-Tx mice. B: Foxp3 and Helios expression 
by CD4+ T cells in the spleen and CLNs of non-Tx and Tx mice were determined by 
flow cytometry. Profiles are representative of 5 mice per group. Ratio of Helios−Foxp3+ 
to Helios+Foxp3+ cells is presented as the mean ± SD of 3 mice per group. *p <0.05 vs. 
non-Tx mice. C: Foxp3 and CD304 expression by CD4+ T cells in the spleen and CLNs 
of non-Tx and Tx mice were determined by flow cytometry. Profiles are representative 
of 3 mice per group. Ratio of CD304−/lowFoxp3+ to CD304highFoxp3+ cells is presented 
as the mean ± SD of 3 mice per group. *p <0.05 vs. non-Tx mice.  
 
Figure 6 In vitro induction of pTreg cells. A: Freshly isolated naïve T cells (5 × 104 
cells/well) from the spleen of non-Tx and Tx mice were stimulated with anti-CD3/28 
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mAbs-coated bead to cell ratio of 0.25:1 and 30 U/ml of IL-2 in the presence of 1, 5, or 
10 ng/ml of TGF-β. After culture for 4 days, intracellular Foxp3 and Helios expression 
were determined by flow cytometry. Representative results of 3 independent 
experiments are shown. B: Proportions of Helios−Foxp3+ cells in non-Tx and Tx mice. 
Results are presented as the mean ± SD of triplicates from 3 independent experiments. 
*p <0.05, **p <0.01 vs. non-Tx mice.  
 
Figure 7 mRNA expression of TGF-βR and Smad in naïve CD4+ T cells from Tx mice. 
Naïve CD4+ T cells from the spleen of non-Tx and Tx mice at 10−12 weeks of age were 
used to determine TGF-βRI, II, III, Smad2, Smad3, and Smad4 mRNA expression by 
quantitative RT-PCR. Target mRNA expression is relative to β-actin (×10−3). Results are 
presented as the mean ± SD of 4 mice per group. *p <0.05, **p <0.01 vs. non-Tx mice. 
 
Figure 8 Cytokine production by Treg cells from Tx mice. A, B: Foxp3−CD4+ (A) and 
Foxp3+CD4+ (B) cells among CD4+ T cells from the CLNs of non-Tx and Tx mice at 10 
weeks of age were stimulated with 20 ng/ml of PMA and 500 ng/ml of ionomycin. After 
culture for 6 h, IFN-γ-, IL-4-, IL-2-, IL-17-, and IL-10-producing cells were detected by 
intracellular staining. C, D: Intracellular IFN-γ production and CD62L expression of 
Treg (Foxp3+CD4+), pTreg (Foxp3+Helios−CD4+), and tTreg (Foxp3+Helios+CD4+) cells 
from non-Tx and Tx mice were analyzed by flow cytometry. Results are representative 
of 2 independent experiments. Results are presented as the mean ± SD of 4 mice per 
group. **p <0.01 vs. non-Tx mice. E: Purified Treg cells (1 × 105 cells/well) from the 
spleen of non-Tx and Tx mice were stimulated with anti-CD3/28 mAbs-coated beads at 
a 2:1 bead to cell ratio and 2000 U/ml of IL-2 for 10 days. IFN-γ concentrations of the 
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culture supernatants at 0−3 and 7−10 days were analyzed by ELISA. Results are 
presented as the mean ± SD of 3 mice per group. **p <0.01 vs. non-Tx mice. 
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